Literature DB >> 9821800

Determination of urinary and serum pentosidine and its application to elder patients.

K Yoshihara1, K Nakamura, M Kanai, Y Nagayama, S Takahashi, N Saito, M Nagata.   

Abstract

Pentosidine, a fluorescent cross-linking compound, accumulates in extracellular matrix, especially in the collagen, and is formed by the nonenzymatic process of advanced Maillard reaction. We developed a method of determination of pentosidine and tried to examine its level in urine and serum of elder patients. The method, which involves the hydrolysis of samples, pretreatment using a CF-11 cellulose column and HPLC quantification, resulted in a high recovery (94.3%) of pentosidine with low coefficient of variation (8-10%) of total analysis. Serum and urinary levels of pentosidine in control subjects gradually increased with age. Elder patients with cerebral infarction showed higher levels of serum and urinary pentosidine as compared with those with senile dementia and other geriatric disorders. These results suggest that serious damage to systemic vascular tissues has already occurred in these patients due to glycation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821800     DOI: 10.1248/bpb.21.1005

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  12 in total

1.  Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Yumiko Shiraki; Shiro Tanaka; Tsuyoshi Higuchi; Mitsuru Saito
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

Review 2.  Pathways of the Maillard reaction under physiological conditions.

Authors:  Christian Henning; Marcus A Glomb
Journal:  Glycoconj J       Date:  2016-06-13       Impact factor: 2.916

3.  Pentosidine in osteoarthritis: HPLC determination in body fluids and in tissues.

Authors:  Pavel Spacek; Milan Adam
Journal:  Rheumatol Int       Date:  2006-03-31       Impact factor: 2.631

4.  Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.

Authors:  Mihaela Oleniuc; Irina Secara; Mihai Onofriescu; Simona Hogas; Luminita Voroneanu; Dimitrie Siriopol; Adrian Covic
Journal:  Maedica (Buchar)       Date:  2011-10

5.  Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study.

Authors:  M T Schram; N Chaturvedi; C G Schalkwijk; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2005-02-04       Impact factor: 10.122

6.  The association between urinary pentosidine levels and cognition in drug-naïve patients with Parkinson's disease.

Authors:  Shusaku Omoto; Mitsuru Saito; Hidetomo Murakami; Tomotaka Shiraishi; Tomomichi Kitagawa; Takeo Sato; Hiroki Takatsu; Teppei Komatsu; Kenichiro Sakai; Tadashi Umehara; Hidetaka Mitsumura; Yasuyuki Iguchi
Journal:  Neurol Sci       Date:  2022-08-12       Impact factor: 3.830

7.  Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Shiro Tanaka; Mitsuru Saito; Masao Fukunaga; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

8.  Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study.

Authors:  E Gineyts; F Munoz; C Bertholon; E Sornay-Rendu; R Chapurlat
Journal:  Osteoporos Int       Date:  2009-05-07       Impact factor: 4.507

Review 9.  Trabecular bone mechanical properties in patients with fragility fractures.

Authors:  Jaclynn M Kreider; Steven A Goldstein
Journal:  Clin Orthop Relat Res       Date:  2009-02-27       Impact factor: 4.176

10.  Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.

Authors:  Jan Vaculík; Martin Braun; Pavel Dungl; Karel Pavelka; Jan J Stepan
Journal:  BMC Musculoskelet Disord       Date:  2016-07-22       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.